Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COMy 2023 | The changing role of autoSCT in the treatment of multiple myeloma in the era of novel agents

Eileen Boyle • 11 May 2023
COMy 2023
Multiple Myeloma

In this video, Eileen Boyle, MD, PhD, University College London, London, UK, comments on how the treatment landscape of multiple myeloma has transformed over the years, emphasizing the changing role of autologous stem cell transplantation (autoSCT) in the era of novel agents. This interview took place at the 9th World Congress on Controversies in Multiple Myeloma (COMy) 2023, held in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Eileen Boyle

1:11
The PANGEA model: enhancing risk assessment for individuals with high-risk smoldering myeloma
Eileen Boyle • 11 May 2023
1:05
Approaching patients with penta-refractory myeloma: the importance of clinical trials
Eileen Boyle • 11 May 2023
0:56
How do we define smoldering multiple myeloma?
Eileen Boyle • 11 May 2023
1:20
Identifying high-risk multiple myeloma patient subgroups using genetic and clinical factors
Eileen Boyle • 12 Dec 2022

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals